-

Musa Tariq Joins Guardant Health Board of Directors

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the appointment of Musa Tariq to its board of directors, effective March 6. Currently the chief marketing officer for GoFundMe, the world’s leading fundraising platform, Tariq is a distinguished marketing executive with experience leading global consumer brands.

“We are very pleased to welcome Musa Tariq to our board of directors,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “Musa brings a wealth of knowledge and expertise in building some of the world’s most recognized brands. His insights will be extremely valuable as we continue to build our brand and shape the company’s next chapter to empower every individual to stay one step ahead of cancer.”

Since joining GoFundMe in January 2021, Tariq has been recognized for his leadership in Forbes’ Entrepreneurial CMO List 2022, and in Insider’s Most Innovative CMOs of 2022. Before his role with GoFundMe, Tariq was global head of marketing for Airbnb Experiences where he drove brand awareness and adoption of that rapidly growing part of Airbnb’s business. Prior to Airbnb, he was chief brand officer at Ford Motor Company and also held marketing leadership roles at Apple, Nike and Burberry.

“I am excited to join the Guardant Health board at such a pivotal time in the company’s evolution,” said Tariq. “Guardant is a leader in helping patients at all stages of cancer live longer and healthier lives, and now they’ve developed a simple blood test to find cancer early, when it’s most treatable. I look forward to working with the company’s leadership team to advance its mission to transform the future of cancer care.”

A distinguished counselor to iconic and emerging global brands, Tariq currently serves as an advisor to MasterClass, The British Fashion Council, Felix Capital and several other starts ups. He has a B.S. in Geography and Economics from London School of Economics.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer, and Guardant Reveal™ for early-stage cancer. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.

Contacts

Investor Contact:
Alex Kleban
investors@guardanthealth.com
+1 657-254-5417

Media Contact:
Michael Weist
press@guardanthealth.com
+1 317-371-0035

Guardant Health, Inc.

NASDAQ:GH

Release Versions

Contacts

Investor Contact:
Alex Kleban
investors@guardanthealth.com
+1 657-254-5417

Media Contact:
Michael Weist
press@guardanthealth.com
+1 317-371-0035

More News From Guardant Health, Inc.

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions

PALO ALTO, Calif. & ROCHESTER, Minn.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for Clinical Trials in Oncology today announced publication of the largest study to date evaluating circulating tumor DNA (ctDNA) for MRD detection in patients with resected stage III colon cancer after surgery and before adjuvant chemotherapy. Results of the study, published in the Journal of Clinical Oncology...

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with BRAFTOVI® (encorafenib) in combination with cetuximab and chemotherapy in accordance with the approved product labeling. The accelerated approval was su...

Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck’s oncology portfolio using the Guardant Infinity™ Smart platform. Under the multi-year collaboration agreement, Guardant and Merck aim to: Use Guardant’s portfolio of liquid and tissue biopsy tests as clinical trial enrolling...
Back to Newsroom